Invitrogen™ Equine VEGF-A ELISA Kit

Catalog No.	Quantity
EE9RBX5	5 x 96 Tests
EE9RBX10	10 x 96 Tests
EE9RB	96 Tests

Catalog No. EE9RBX5 Supplier Invitrogen™ Supplier No. EE9RBX5

Description

ELISA

Equine VEGF-A quantitates equine VEGF-A in serum, plasma, supernatant. The assay will exclusively recognize both natural and recombinant equine VEGF-A.

VEGF (vascular endothelial growth factor) which is a 45 kDa homodimeric, disulfide-linked glycoprotein involved in angiogenesis which promotes tumor progression and metastasis. VEGF has a variety of effects on vascular endothelium, including the ability to promote endothelial cell viability, mitogenesis, chemotaxis, and vascular permeability. The VEGF family currently includes VEGF-A, VEGF-B, VEGF-C, VEGF-D, VEGF-E, and PIGF. VEGF and its receptor system have been shown to be the fundamental regulators in the cell signaling of angiogenesis. Most tumors have the absolute requirement of angiogenesis, and VEGF has been described as the most potent angiogenic cytokine linked to this process. To date 5 different isoforms of VEGF have been described. These isoforms are generated as the result of alternative splicing from a single VEGF gene. These various isoforms have been shown to bind to two tyrosine-kinase receptors flt-1 (VEGFR-1) and flk-1/KDR (VEGFR-2), which have been found to be expressed almost exclusively on endothelial cells. VEGF and its high-affinity binding receptors, the tyrosine kinases FLK1 and FLT1, are thought to be important for the development of embryonic vasculature. Studies have shown that an alternately spliced form of FLT1 produces a soluble protein, termed sFLT1, which binds vascular endothelial growth factor with high affinity, playing an inhibitory role in angiogenesis. Elevated levels of VEGF is linked to POEMS syndrome (Polyneuropathy, Organomegaly, Endocrinopathy, Monoclonal gammopathy, Skin changes) also known as Crow-Fukase syndrome which affects multiple organs in the body.

Specifications

• Accession Number: angiogenic factor; etID309976.16; eVEGF120; eVEGF164; human VEGF121 homolog; MGC70609; MVCD1; ovine vascular endothelial growth factor; RP1-261G23.1; unnamed protein product; VAS; vascular endothelial growth factor; vascular endothelial growth factor (VEGF) precursor; vascular endothelial growth factor 121 isoform; vascular endothelial growth factor 164; vascular endothelial growth factor 165 b; vascular endothelial growth factor 182 isoform; vascular endothelial growth factor 188; vascular endothelial growth factor 188 isoform; vascular endothelial growth factor 189; vascular endothelial growth factor A; vascular endothelial growth factor A121; vascular endothelial growth factor A165; vascular endothelial growth factor Aa; Vascular endothelial growth factor A-A; vascular endothelial growth factor isoform 165; Vascular permeability factor; Vasculotropin; vegf; VEGF1; VEGF164; VEGF182; VEGF188; VEGFA; vegf-a; vegfaa; VEGF-A-A; VEGFMGC70609; VPF; VPF ant; wu:fj82c06
• Assay Range: 4 to 1,000 pg/mL
• Assay Sensitivity: 4 pg/mL
• Conjugate: HRP
• Product Type: ELISA
• Sample Type: Plasma, Serum, Supernatant
• For Use With (Equipment): Colorimetric Microplate Reader
• Gene ID (Entrez): 100033839
• Gene Symbol: VEGFA
• Interassay CV: <12%
• Intraassay CV: <10
• Kit Contents: Pre-coated 96 well plate, Standard, Assay Diluent concentrate, Biotinylated Detection Antibody, SAV-HRP, Wash Buffer, Chromogen, Stop Solution, Adhesive Plate Covers
• Label or Dye: HRP
• Quantity: 5 x 96 Tests
• Regulatory Status: RUO
• Sample Volume: Plasma 50 μL, Serum 50 μL, Supernatant 50 μL
• Storage Requirements: 2°C to 8°C
• Target: VEGF
• Test Time: 1 hrs 20 mins
• Total Assay Time: 4 hrs 45 mins

Safety and Handling

WARNING: Reproductive Harm - www.P65Warnings.ca.gov